SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jacobsen, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobsen, P. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Preventing End-Stage Renal Disease in Diabetic Patients — Dual Blockade of the Renin-Angiotensin System (Part II)

Peter Karl Jacobsen

Steno Diabetes Center, Gentofte, Denmark, pkjacobsen{at}dadlnet.dk

Diabetic nephropathy is a major cause of diabetes related morbidity and mortality. The first part of the current review was published in the last issue of this journal and discussed the impotant role of the renin-angiotensin system (RAS) in diabetic nephropathy and the genetic influence on development of end-stage renal disease (ESRD) in diabetic patients. This second part of the review focus on the potential improvement of the current treatment strategy to slow down the loss of kidney function using dual blockade of the RAS with both ACE-inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs). Substantial evidence from short-term studies using surrogate endpoints indicates a beneficial impact of dual blockade of the RAS, not obtainable with single agent blockade alone, both in diabetic and non-diabetic renal disease. This conclusion has been confirmed and extended in a longterm trial with regard to prevention of ESRD in non-diabetic renal disease. Results indicate that dual blockade of the RAS may further slow down, but not arrest progressive loss of renal function. However, studies defining the optimal dose of ACE-I / ARBs without additional adverse effects are essential to ensure relevant comparison with dual blockade therapy. Trials using primary renal endpoints in diabetic nephropathy are still needed, and will finally establish the role of dual blockade of the RAS in a clinical setting.

Key Words: ACE-I • Angiotensin II receptor blockade • Dual blockade • Renin-angiotensin-aldosterone system • Albuminuria • Blood pressure • Diabetic nephropathy

References

  • Powers AC Diabetes Mellitus. In: Braunwald E, Fauci AS, Isselbacher KJ et al., editors. Harrison Online. New York: The McGraw-Hill Companies, 2002.
  • Parving H-H., sterby R., Ritz E. Diabetic nephropathy. In: Brenner BM, editor. The Kidney. Philadelphia: WB Saunders, 2000:1731-73.
  • Parving H-H., Viberti GC, Keen H., Christiansen JS, Lassen NA Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983;32(9):943-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Porte D., Jr., Schwartz MW Diabetes complications: why is glucose potentially toxic? Science 1996;272: 699-700.[Web of Science][Medline] [Order article via Infotrieve]
  • Cooper ME Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cooper ME Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brenner BM, Meyer TW, Hostetter TH Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307:652-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Hostetter TH, Rennke HG, Brenner BM The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72: 375-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.[Free Full Text]
  • Fogo AB Progression and potential regression of glomerulosclerosis. Kidney Int 2001;59:804-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rossing P. Promotion, prediction and prevention of progression of nephropathy in Type 1 diabetes mellitus. Diabet Med 1998;15:900-19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hovind P., Rossing P., Tarnow L., Smidt UM, Parving H-H. Progression of diabetic nephropathy. Kidney Int 2001; 59:702-09.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jacobsen P., Tarnow L., Carstensen B., Hovind P., Poirier O., Parving H-H. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 2003;14:2843-50.[Abstract/Free Full Text]
  • Bjorck S., Mulec H., Johnsen SA, Norden G., Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43.[Web of Science][Medline] [Order article via Infotrieve]
  • Kasiske BL, Kalil RS, Ma JZ, Liao M., Keane WF Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129-38.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
  • Bilous RW Baseline and change in proteinuria and the risk of renal functional loss in the Irbesartan Diabetic Nephropathy Trial (IDNT). Diabet Med 2003;20(suppl.2):1-33.[Web of Science][Medline] [Order article via Infotrieve]
  • Ruggenenti P., Perna A., Remuzzi G. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003;63:2254-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Zeeuw D., Remuzzi G., Parving H-H et al. Proteinuria reduction during antihypertensive therapy predicts renal and cardio-vascular protection in patients with Type 2 diabetic nephropathy. Diabetologia 2003;46(Suppl. 2):A339.[CrossRef]
  • De Jong PE, Navis G., De Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mogensen CE Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Eday)1982;285:685-8.
  • Parving H-H., Andersen AR, Smidt UM, Svendsen PA Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Parving H-H., Jacobsen P., Rossing K., Smidt UM, Hommel E., Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996; 49:1778-82.[Web of Science][Medline] [Order article via Infotrieve]
  • Rossing P., Hougaard P., Borch-Johnsen K., Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996;313:779-84.[Abstract/Free Full Text]
  • Mooser V., Nussberger J., Juillerat L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990;15:276-82.[Web of Science][Medline] [Order article via Infotrieve]
  • van den Meiracker AH, Man in `t Veld AJ, Admiraal PJ et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992;10:803-12.[Web of Science][Medline] [Order article via Infotrieve]
  • Rousseau MF, Konstam MA, Benedict CR et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994; 73:488-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Roig E., Perez-Villa F., Morales M. et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7.[Abstract/Free Full Text]
  • Hollenberg NK, Fisher ND, Price DA Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.[Abstract/Free Full Text]
  • Ritz E. Chymase: a potential culprit in diabetic nephropathy? J Am Soc Nephrol 2003;14:1952-4.[Free Full Text]
  • Huang XR, Chen WY, Truong LD, Lan HY Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14: 1738-47.[Abstract/Free Full Text]
  • Vanhoutte PM Endothelium and control of vascular function. State of the Art lecture. Hypertension 1989; 13(6 Pt 2):658-67.[Abstract/Free Full Text]
  • Allen TJ, Cao Z., Youssef S., Hulthen UL, Cooper ME Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997; 46:1612-18.[Abstract]
  • Nabokov A., Amann K., Gassmann P., Schwarz U., Orth SR, Ritz E. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 1998;13:173-6.[Abstract/Free Full Text]
  • de Gasparo M., Catt KJ, Inagami T., Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.[Abstract/Free Full Text]
  • Burns KD Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36449-67.
  • Wolf G., Ziyadeh FN, Thaiss F. et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin Type 2 receptor. J Clin Invest 1997;100:1047-58.[Web of Science][Medline] [Order article via Infotrieve]
  • Cao Z., Kelly DJ, Cox A. et al. Angiotensin Type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 2000;58:2437-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cao Z., Bonnet F., Candido R. et al. Angiotensin Type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002;13:1773-87.[Abstract/Free Full Text]
  • Wolf G. "The road not taken": role of angiotensin II Type 2 receptor in pathophysiology. Nephrol Dial Transplant 2002; 17:195-8.[Free Full Text]
  • Cao Z., Forbes JM, Cooper ME Pivotal role of the AT2 receptor subtype in mediating angiotensin II induced renal VEGF expression. J Am Soc Nephrol 2002;13:149A.[CrossRef]
  • Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000;15(Suppl 6):61-3.[Free Full Text]
  • Ma L., Fogo AB Role of angiotensin II in glomerular injury. Semin Nephrol 2001;21:544-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Komine N., Khang S., Wead LM, Blantz RC, Gabbai FB Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002;39:159-64.[Web of Science][Medline] [Order article via Infotrieve]
  • Campbell DJ, Kladis A., Valentijn AJ Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995;26: 233-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Cao Z., Cooper ME, Wu LL et al. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 2000;36:561-8.[Abstract/Free Full Text]
  • Ots M., Mackenzie HS, Troy JL, Rennke HG, Brenner BM Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998;9:224-30.[Abstract]
  • Ma L-J., Nakamura S., Nakamura I., Marcantoni Cfab. High dose angiotensin II type 1 receptor antagonist (AT1RA) and angiotensin converting enzyme inhibitor (ACEI)in Regression of Glomerulasclerosis. J Am Soc Nephrol 2002;13:342A.
  • Cao Z., Bonnet F., Davis B., Allen TJ, Cooper ME Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Londay)2001;100:591-9.
  • Zoja C., Corna D., Camozzi D. et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898-908.[Abstract/Free Full Text]
  • Menard J., Campbell DJ, Azizi M., Gonzales MF Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997;96:3072-8.[Abstract/Free Full Text]
  • Webb RL, Navarrete AE, Davis S., de Gasparo M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J Hypertens 1998;16:843-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bos H., Henning RH, De Boer E. et al. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney Int 2002;61:473-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Remuzzi A., Gagliardini E., Donadoni C. et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885-94.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hollenberg NK Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension 2000;35(1 Pt 2):150-4.[Abstract/Free Full Text]
  • Azizi M., Chatellier G., Guyene TT, Murieta-Geoffroy D., Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995;92:825-34.[Abstract/Free Full Text]
  • Azizi M., Guyene TT, Chatellier G., Wargon M., Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997;29:634-40.[Abstract/Free Full Text]
  • Mogensen CE, Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.[Abstract/Free Full Text]
  • Jacobsen P., Andersen S., Rossing K., Hansen BV, Parving H-H. Dual blockade of the renin-angiotensin system in Type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002;17:1019-24.[Abstract/Free Full Text]
  • Rossing K., Christensen PK, Jensen BR, Parving H-H. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100.[Abstract/Free Full Text]
  • Jacobsen P., Andersen S., Jensen BR, Parving H-H. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type I Idiabetic patients with diabetic nephropathy. J Am M Soc Nephrol 2003;14:992-9.[CrossRef]
  • Parvanova A., Pisoni R., Dimitrov BD et al.Relative renoprotective effect of ACE inhibitors (ACEi), angiotensin II antagonists (ATA), ACEi and ATA combination and dihydropyridine calcium channel blockers (dCCBs) in overt diabetic nephropathy of Type 2 diabetes. J Am Soc Nephrol 2001;12:153A.[CrossRef]
  • Ruilope LM, Aldigier JC, Ponticelli C., Oddou-Stock P., Botteri F., Mann JF Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95.[Web of Science][Medline] [Order article via Infotrieve]
  • Russo D., Minuteutolo R., Pisani A. et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.[Web of Science][Medline] [Order article via Infotrieve]
  • Ferrari P., Marti HP, Pfister M., Frey FJ Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002;20: 125-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kincaid-Smith P., Fairley K., Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002;17:597-601.[Abstract/Free Full Text]
  • Luno J., Barrio V., Goicoechea MA et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002;62(Suppl 82): 47-52.[CrossRef][Medline] [Order article via Infotrieve]
  • Tylicki L., Rutkowski P., Renke M., Rutkowski B. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Am J Nephrol 2002;22:356-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Campbell R., Sangalli F., Perticucci E. et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63: 1094-103.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jacobsen P., Andersen S., Rossing K., Jensen BR, Parving H-H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Rossing K., Jacobsen P., Pietraszek L., Parving H-H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74.[Abstract/Free Full Text]
  • Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282-89.[Web of Science][Medline] [Order article via Infotrieve]
  • Gibbs CR, Beevers DG, Lip GY The management of hypertensive disease in black patients. QJM 1999;92: 187-92.[Abstract/Free Full Text]
  • Exner DV, Dries DL, Domanski MJ, Cohn JN Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.[Abstract/Free Full Text]
  • Andersen S., Rossing P., Juhl TR, Deinum J., Parving H-H. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002;17: 1413-18.[Abstract/Free Full Text]
  • Laverman GD, Navis G., Henning RH, De Jong PE, De Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62: 1020-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lijnen P., Fagard R., Staessen J., Verschueren LJ, Amery A. Dose response in captopril therapy of hypertension. Clin Pharmacol Ther 1980;28:310-15.[Web of Science][Medline] [Order article via Infotrieve]
  • Gomez HJ, Cirillo VJ, Sromovsky JA et al. Lisinopril doseresponse relationship in essential hypertension. Br J Clin Pharmacol 1989;28:415-20.[Web of Science][Medline] [Order article via Infotrieve]
  • Whalen JJ Definition of the effective dose of the converting-enzyme inhibitor benazepril. Am Heart J 1989; 117:728-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Eber B., Brussee H., Rotman B., Kramer R., Klein W. Evaluation of the antihypertensive effect of lisinopril compared with nifedipine in patients with mild to severe essential hypertension. Angiology 1992;43:482-9.[Abstract/Free Full Text]
  • Reeves RA, Lin CS, Kassler-Taub K., Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998;31:1311-16.[Abstract/Free Full Text]
  • Rossing K., Christensen PK, Hansen BV, Carstensen B., Parving H-H. Optimal dose of candesartan for renoprotection in Type 2 diabetic patients with nephropathy: A double-blind randomized cross-over study. Diabetes Care 2003;26: 150-5.[Abstract/Free Full Text]
  • Buter H., Navis G., Dullaart RP, De Zeeuw D., De Jong PE Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001;16:771-5.[Abstract/Free Full Text]
  • Andersen S., Jacobsen P., Tarnow L., Rossing P., Juhl TR, Parving H-H. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2003;18:293-7.[Abstract/Free Full Text]
  • Gansevoort RT, De Zeeuw D., De Jong PE Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993;44:579-84.[Web of Science][Medline] [Order article via Infotrieve]
  • Bakris GL, Weir MR Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.[Abstract/Free Full Text]
  • Apperloo AJ, De Zeeuw D., De Jong PE A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Hansen HP, Rossing P., Tarnow L., Nielsen FS, Jensen BR, Parving H-H. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995;47:1726-31.[Web of Science][Medline] [Order article via Infotrieve]
  • Freudenthaler SM, Schreeb K., Korner T., Gleiter CH Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 1999;29:816-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Freudenthaler SM, Schenck T., Lucht I., Gleiter CH Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system. Br J Clin Pharmacol 1999;48:631-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gossmann J., Burkhardt R., Harder S. et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II Type 1 receptor-dependent pathway. Kidney Int 2001;60:83-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shoji T., Suzuki A., Takabataka Y. et al. The impact of the combination of losartan and enalapril on erythropoiesis in Japanese patients with chronic glomerulonephritis. J Am Soc Nephrol 2001;12:411A.
  • Andersen S., Tarnow L., Rossing P., Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-06.[Web of Science][Medline] [Order article via Infotrieve]
  • Buter H., van Tol A., Navis GJ et al. Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer. Diabet Med 2000;17: 550-2.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Andersen S., Tank JE, Brenner BM Renal and Systemic Manifestations of Glomerular Disease. In: Brenner BM, editor. The Kidney. Philadelphia: WB Saunders, 2000:1871-1900.
  • Laverman GD, Andersen S., Rossing P., Navis G., De Zeeuw D., Parving H-H. Dose-dependent reduction of proteinuria by losartan does not require reduction of blood pressure. J Am Soc Nephrol 2002;13:265A.
  • Brenner BM, Cooper ME, De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Parving H-H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
  • Huang ES, Meigs JB, Singer DE The effect of interventions to prevent cardiovascular disease in patients with Type 2 diabetes mellitus. Am J Med 2001;111:633-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Andersen S., Blouch K., Bialek J., Deckert M., Parving H-H., Myers BD Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58(5):2129-37.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Deen WM, Satvat B. Determinants of the glomerular filtration of proteins. Am J Physiol 1981;241:F162-F170.[Web of Science][Medline] [Order article via Infotrieve]
  • Deckert T., Kofoed-Enevoldsen A., Vidal P., Norgaard K., Andreasen HB, Feldt-Rasmussen B. Size- and charge selectivity of glomerular filtration in Type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 1993; 36:244-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lansang MC, Price DA, Laffel LM et al. Renal vascular responses to captopril and to candesartan in patients with Type 1 diabetes mellitus. Kidney Int 2001;59:1432-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Muirhead N., Feagan BF, Mahon J. et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with Type 2 diabetes mellitus: A Placebo-Controlled Trial. Current Therapeutic Research 1999;60:650-60.[CrossRef]
  • Lacourciere Y., Belanger A., Godin C. et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive Type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hilgers KF, Mann JF ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002;13:1100-08.[Free Full Text]
  • Price DA, Porter LE, Gordon M. et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382-91.[Abstract/Free Full Text]
  • Jacobsen P., Rossing K., Rossing P. et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998;53:1002-06.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parving H-H., Jacobsen P., Tarnow L. et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996;313:591-4.[Abstract/Free Full Text]
  • Andersen S., Tarnow L., Cambien F. et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 2002;62:192-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bos H., Andersen S., Rossing P. et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl 2000; 75:S32-S37.[Medline] [Order article via Infotrieve]
  • Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
  • Stergiou GS, Skeva II, Baibas NM et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000;35:937-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Weir MR, Weber MA, Neutel JM, Vendetti J., Michelson EL, Wang RY Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001;14(6 Pt 1):567-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Baruch L., Anand I., Cohen IS, Ziesche S., Judd D., Cohn JN Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99:2658-64.[Abstract/Free Full Text]
  • Hamroff G., Katz SD, Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-2.[Abstract/Free Full Text]
  • McKelvie RS, Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD)pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.[Abstract/Free Full Text]
  • Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.[Abstract/Free Full Text]
  • McMurray JJV, Östergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kobori H., Harrison-Bernard LM, Navar LG Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002;61:579-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kobori H., Nishiyama A., Navar LG Urinary angiotensinogen originates from kidney in angiotensin (Ang) IIinduced hypertension. J Am Soc Nephrol 2002;13:147A.[CrossRef]
  • Kobori H., Nishiyama A., Harrison-Bernard LM, Navar LG Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension 2003; 41:42-49.[Abstract/Free Full Text]
  • Thongboonkerd V., Klein JB, Pierce WM, Jevans AW, Arthur JM Sodium loading changes urinary protein excretion: a proteomic analysis. Am J Physiol Renal Physiol 2003;284(6):F1155-63. Epub 2003 Feb 11.[Abstract/Free Full Text]
  • Nakao N., Yoshimura A., Morita H., Inui K., Ideura T. Effect of timing of administration on the antihypertensive and antiproteinuric activity of angiotensin-converting enzyme inhibitor. J Am Soc Nephrol 2002;13:243A.
  • Haverdings RF, Haas M., Navis G. et al. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats. Br J Pharmacol 2002;136: 1107-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haverdings RF, De Zeeuw D., Moolenaar F. Subcutaneous administration of captopril-lysozyme: improved antiproteinuric response by 24-Hour exclusive renal ACE inhibition. J Am Soc Nephrol 2002;13:266A.
  • Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001;19:829-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ibrahim HN, Hostetter TH Aldosterone in renal disease. Curr Opin Nephrol Hypertens 2003;12(2):159-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Bravo EL Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Curr Hypertens Rep 2003;5:122-5.[Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sato A., Hayashi K., Naruse M., Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8.[Abstract/Free Full Text]
  • Krum H., Nolly H., Workman D. et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.[Abstract/Free Full Text]
  • Chrysostomou A., Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925-6.[Free Full Text]
  • Weber MA Vasopeptidase inhibitors. Lancet 2001; 358:1525-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cao Z., Burrell LM, Tikkanen I., Bonnet F., Cooper ME, Gilbert RE Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001;60:715-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Taal MW, Nenov VD, Wong W. et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001; 12:2051-9.[Abstract/Free Full Text]
  • Coats AJ Omapatrilat--the story of Overture and Octave. Int J Cardiol 2002;86:1-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 2, 55-68 (2005)
DOI: 10.3317/jraas.2005.011
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jacobsen, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobsen, P. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement